The stock of Chimerix Inc (NASDAQ:CMRX) is a huge mover today! About 257,976 shares traded hands. Chimerix Inc (NASDAQ:CMRX) has declined 9.25% since March 15, 2016 and is downtrending. It has underperformed by 14.74% the S&P500.
The move comes after 6 months positive chart setup for the $227.62M company. It was reported on Oct, 18 by Barchart.com. We have $10.92 PT which if reached, will make NASDAQ:CMRX worth $286.80M more.
Analysts await Chimerix Inc (NASDAQ:CMRX) to report earnings on November, 3. They expect $-0.46 EPS, up 34.29% or $0.24 from last year’s $-0.7 per share. After $-0.39 actual EPS reported by Chimerix Inc for the previous quarter, Wall Street now forecasts 17.95% negative EPS growth.
Chimerix Inc (NASDAQ:CMRX) Ratings Coverage
Out of 7 analysts covering Chimerix Inc (NASDAQ:CMRX), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. Chimerix Inc has been the topic of 16 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was downgraded by JP Morgan on Tuesday, December 29 to “Neutral”. Morgan Stanley downgraded the stock to “Underweight” rating in Tuesday, February 23 report. The stock of Chimerix Inc (NASDAQ:CMRX) has “Equal-Weight” rating given on Tuesday, February 23 by Barclays Capital. The stock of Chimerix Inc (NASDAQ:CMRX) earned “Buy” rating by Brean Capital on Thursday, August 6. The rating was initiated by FBR Capital with “Outperform” on Tuesday, August 18. The rating was downgraded by FBR Capital on Monday, December 28 to “Mkt Perform”. The firm has “Overweight” rating given on Monday, December 28 by Piper Jaffray. Barclays Capital maintained it with “Overweight” rating and $12 target price in Tuesday, December 29 report. The stock has “Buy” rating given by UBS on Thursday, December 17. FBR Capital maintained it with “Mkt Perform” rating and $10 target price in Tuesday, February 23 report.
According to Zacks Investment Research, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.27, from 1.07 in 2016Q1. The ratio dropped, as 23 funds sold all Chimerix Inc shares owned while 37 reduced positions. 16 funds bought stakes while 32 increased positions. They now own 30.87 million shares or 5.26% less from 32.59 million shares in 2016Q1.
Deere Company reported 60,832 shares or 0.01% of all its holdings. Renaissance Technology Lc has 265,265 shares for 0% of their US portfolio. Los Angeles Cap Management Equity Research holds 81,945 shares or 0% of its portfolio. Blackrock Group Inc Limited accumulated 22,805 shares or 0% of the stock. Axa holds 0% of its portfolio in Chimerix Inc (NASDAQ:CMRX) for 138,980 shares. Apriem Advsrs owns 2,000 shares or 0% of their US portfolio. Alpinvest Prns Bv holds 0.16% of its portfolio in Chimerix Inc (NASDAQ:CMRX) for 20,769 shares. Us Retail Bank De holds 35,500 shares or 0% of its portfolio. Bnp Paribas Arbitrage accumulated 1,668 shares or 0% of the stock. Quantitative Investment Management Ltd Limited Liability Company owns 35,100 shares or 0.01% of their US portfolio. Panagora Asset Mgmt Inc, a Massachusetts-based fund reported 467,870 shares. The New York-based Secor Advsr L P has invested 0.01% in Chimerix Inc (NASDAQ:CMRX). Susquehanna Gru Inc Ltd Liability Partnership last reported 0% of its portfolio in the stock. Blackrock Fund Advsr holds 1.69M shares or 0% of its portfolio. The New York-based D E Shaw Com has invested 0% in Chimerix Inc (NASDAQ:CMRX).
Insider Transactions: Since May 10, 2016, the stock had 3 insider buys, and 1 insider sale for $241,560 net activity. The insider MARIO ERNEST bought $45,328. 22,417 shares with value of $100,226 were bought by Berrey M Michelle on Monday, August 29. Another trade for 5,000 shares valued at $25,163 was sold by LEONARD JOHN M..
More recent Chimerix Inc (NASDAQ:CMRX) news were published by: Fool.com which released: “Here’s Why Chimerix Inc Jumped 14.3% in April” on May 06, 2016. Also Fool.com published the news titled: “Why Chimerix Inc. Is Up Big Today” on January 19, 2016. Valuewalk.com‘s news article titled: “Chimerix, Inc. (CMRX)Tanks After Report Of Failed Late State Trial” with publication date: December 28, 2015 was also an interesting one.
CMRX Company Profile
Chimerix, Inc. (Chimerix), incorporated on April 7, 2000, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.